RachelB.SalitMD

Oncology • Seattle, WA

Hematologic Oncology

Instructor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Salit is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salit's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-667-1317

Fax+1 410-328-0267

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
University of MarylandResidency, Internal Medicine, 2004 - 2007
Loyola University Chicago Stritch School of MedicineClass of 2004

Certifications & Licensure

WA State Medical License 2012 - 2025
MD State Medical License 2007 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Jun 25
Completed
Phase 2
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders Start of enrollment: 2009 Aug 25
Terminated
Phase 1
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2010 May 19
Terminated
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Start of enrollment: 2014 Oct 20
ACTIVE_NOT_RECRUITING
PHASE2
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Start of enrollment: 2021 Feb 09
RECRUITING
PHASE2
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis Start of enrollment: 2020 Dec 18
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

2 citations
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Damien Luque Paz, Nico Gagelmann, Lina Benajiba, Jérémie Riou, Rachel Salit
Blood Advances. 2025-02-25
Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
Mihkai M Wickline, Paul A Carpenter, Jeffrey R Harris, Sarah J Iribarren, Kerryn W Reding
Vaccine. 2024-12-02
Barriers and facilitators to routine revaccination among adult Hematopoietic Cell Transplant survivors in the United States: A convergent mixed methods analysis.
Mihkai Wickline, Paul A Carpenter, Jeffrey R Harris, Sarah J Iribarren, Kerryn W Reding
Transplant Infectious Disease. 2024-12-01

Journal Articles

Disability Related to Chronic Graft-Versus-Host Disease After Alternative Donor Hematopoietic Cell Transplantation
Mary E Flowers, Brenda M Sandmaier, Rachel B Salit, Colleen Delaney, Filippo Milano, Stephanie J Lee, Haematologica

Abstracts/Posters

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes
Rachel B. Salit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis
Rachel B. Salit, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplan...
Rachel B. Salit, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019